Synonyms: DF 2755A | DF-2755A
Compound class:
Synthetic organic
Comment: DF2755A inhibits CXCL8 (IL-8) signalling via its endogenous chemokine receptors CXCR1 and CXCR2 [2]. It does not alter the binding affinity of CXCL8 for either receptor, indicating that it is behaving as a negative allosteric modulator (NAM). Activation of the IL-8 pathway has been linked to the development of chemotherapy-induced neuropathic pain. It is predicted that inhibition of this mechanism might offer clinical utility for cancer patients who experience chemotherapy-induced peripheral neuropathy [1].
We show the carboxylic acid parent form for this compound, but DF2755A is used as the sodium salt. |
|
References |
1. Brandolini L, Castelli V, Aramini A, Giorgio C, Bianchini G, Russo R, De Caro C, d'Angelo M, Catanesi M, Benedetti E et al.. (2019)
DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain. Sci Rep, 9 (1): 11729. [PMID:31409858] |
2. Lopes AH, Brandolini L, Aramini A, Bianchini G, Silva RL, Zaperlon AC, Verri Jr WA, Alves-Filho JC, Cunha FQ, Teixeira MM et al.. (2016)
DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain. Pharmacol Res, 103: 69-79. [PMID:26592483] |